Charles River Laboratories CRL Debt-to-equity

Debt-to-equity at other companies

Labcorp HoldingsLH

0.8×+0.1×

Rapid Micro BiosystemsRPID

1.2×+1.1×

Sotera HealthSHC

3.4×-1.2×

Ginkgo BioworksDNA

1×+0.3×

Fortrea Holdings Inc.FTRE

2.1×0.0×

RevvityRVTY

0.5×+0.1×

FAQ

What is Charles River Laboratories's debt-to-equity?

Charles River Laboratories (CRL) reported debt-to-equity of 1.1× in Q2 2026.

How has Charles River Laboratories's debt-to-equity changed year-over-year?

Charles River Laboratories's debt-to-equity increased by 27.7% year-over-year, from 0.8× to 1.1×.

What is the long-term trend for Charles River Laboratories's debt-to-equity?

Over 5 years (2020 to 2025), Charles River Laboratories's debt-to-equity has grown at a -4.1% compound annual growth rate (CAGR), from 1× to 0.8×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.